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Obesity is primarily due to food intake in excess of the body’s energetic requirements, intake that is not only associated with hunger but
also the incentive value of food. The 5-hydroxytryptamine 2C receptor (5-HT2CR) is a target for the treatment of human obesity.
Mechanistically, 5-HT2CRs are positioned to influence both homeostatic feeding circuits within the hypothalamus and reward circuits within
the ventral tegmental area (VTA). Here we investigated the role of 5-HT2CRs in incentive motivation using a mathematical model of
progressive ratio (PR) responding in mice. We found that the 5-HT2CR agonist lorcaserin significantly reduced both ad libitum chow intake
and PR responding for chocolate pellets and increased c-fos expression in VTA 5-HT2CR expressing γ-aminobutyric acid (GABA) neurons,
but not 5-HT2CR expressing dopamine (DA) neurons. We next adopted a chemogenetic approach using a 5-HT2CR
CRE line to clarify the
function of subset of 5-HT2C receptor expressing VTA neurons in the modulation of appetite and food-motivated behavior. Activation of
VTA 5-HT2C receptor expressing neurons significantly reduced ad libitum chow intake, operant responding for chocolate pellets, and the
incentive value of food. In contrast, chemogenetic inhibition of VTA 5-HT2C receptor expressing neurons had no effect on the feeding
behavior. These results indicate that activation of the subpopulation of 5-HT2CR neurons within the VTA is sufficient to significantly reduce
homeostatic feeding and effort-based intake of palatable food, and that this subset has an inhibitory role in motivational processes. These
findings are relevant to the treatment of obesity.
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INTRODUCTION
The activity of the monoamine neurotransmitter 5-hydro-
xytryptamine (5-HT; serotonin) within the brain has a
functional role in the regulation of feeding behavior and
body weight (Blundell, 1986; Hill and Blundell, 1990), and as
such has been a target for obesity medications (Halford et al,
2011; Vickers and Clifton, 2012). These effects of 5-HT are
primarily achieved via action at the G-protein-coupled
5-HT2C receptor (5-HT2CR) subtype, which is mainly, if
not exclusively, expressed within the central nervous system.
Activation of 5-HT2CRs promotes weight loss by decreasing
food intake (Martin et al, 2011; Higgs et al, 2016) through the
modulation of the activity of neuronal pathways regulating
energy balance, including those within the arcuate nucleus of
the hypothalamus (Burke and Heisler, 2015). However,
5-HT2CRs are also positioned to influence motivational
circuits processing rewarding stimuli (Kranz et al, 2010).
Specifically, 5-HT2CRs within the ventral tegmental area
(VTA) (Bubar and Cunningham, 2007; Bubar et al, 2011)
exert an inhibitory effect upon the mesoaccumbens dopa-
mine (DA) system (Di Matteo et al, 2000; Hayes et al, 2009)
which has been implicated in motivational processes and
effort-related choice (Salamone and Correa, 2013). Collec-
tively, these findings suggest that 5-HT2CRs may modulate
feeding not solely by influencing energy homeostasis via the
hypothalamus and functionally related structures, but also by
regulating appetitive motivation (operant responding).
Several behavioral tasks have been used to assess motiva-
tion. One such task is the progressive ratio (PR) schedule, in
which the number of responses required per reinforcer is
progressively increased (Hodos, 1961). The ratio at which the
subject stops responding (the ‘breakpoint’) is regarded as a
measure of motivation (Richardson and Roberts, 1996). The
selective 5-HT2CR agonists lorcaserin ((1R)-8-chloro-1-
methyl-2,3,4,5-tetrahydro-1H-3-benzazepine) (Meltzer and
Roth, 2013), Ro-600175 ((αS)-6-chloro-5-fluoro-α-methyl-
1H-indole-1-ethanamine) and CP-809101 (2-(3-chloroben-
zyloxy)-6-(piperazin-1-yl)pyrazine); and non-selective 5-
HTR agonists with high affinity for 5-HT2CR, such as mCPP
(m-chlorophenylpiperazine) and MK-212 (6-chloro-2-(l-pi-
perazinyl)pyrazine) reduce the breakpoint for food (Bezzina
et al, 2015; Fletcher et al, 2009; Higgins et al, 2012), cocaine
(Burbassi and Cervo, 2008,Harvey-Lewis et al, 2015), ethanol
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(Rezvani et al, 2014), and nicotine (Fletcher et al, 2012),
effects that are blocked by 5-HT2CR antagonists (Bezzina
et al, 2015; Fletcher et al, 2012). Thus, lorcaserin, recently
approved by the US FDA for the treatment of human obesity,
may also have therapeutic potential for nicotine (Higgins
et al, 2012; Levin et al, 2011) and ethanol dependence
(Rezvani et al, 2014). Although 5-HT2CR activation appears
to have an inhibitory role in motivational processes (Filip
et al, 2012; Fletcher et al, 2012), the subset of 5-HT2C
receptor expressing neurons underlying these effects has yet
to be identified.
Here we investigated the role of 5-HT2CRs in food
motivation in mice. To this end, we used a mathematical
model (Bradshaw and Killeen, 2012) derived from Killeen’s
general theory of schedule-controlled behavior, the Mathe-
matical Principles of Reinforcement (MPR, Killeen, 1994),
that enables the experimenter to discriminate between
changes in motor capability and the incentive value of food
in PR performance. First, we analyzed the effect of systemic
administration of 5-HT2CR agonist lorcaserin, on home cage
chow intake and operant responding for chocolate pellets.
Next, we characterized the neurons expressing 5-HT2CRs
within the VTA and their response to lorcaserin as measured
by c-fos immunoreactivity (IR). To investigate the role of
VTA 5-HT2C receptor expressing neurons in the modulation
of appetite and the food-motivated behavior, we used a
chemogenetic approach (designer receptors exclusively
activated by a designer drug, DREADD) (Urban and Roth,
2015) to acutely activate or inhibit this population of neurons
using a recently developed 5-HT2CR
CRE mouse line (Burke
et al, 2016). These studies identify the therapeutic potential
of the activation of a small subset of 5-HT2C receptor
expressing neurons in the reduction of homeostatic feeding
and also more broadly in incentive motivation.
MATERIALS AND METHODS
Subjects
5-HT2CR
CRE mice were intercrossed with ROSA26-stop-
enhanced yellow fluorescent protein (YFP) (B6.129X1-Gt
(ROSA)26Sortm1(EYFP)Cos/J; Jackson Laboratory) to create
a 5-HT2CR
CRE:YPF line (Burke et al, 2016). All the mice were
group-housed and maintained on a 12 h light/dark cycle with
ad libitum access to water and standard laboratory chow diet,
unless otherwise stated. All the experiments were in
accordance with guidelines and approvals of the U.K.
Animals (Scientific Procedures) Act 1986 or the University
of Michigan Committee on the Use and Care of Animals.
Drugs
Lorcaserin HCl (3, 7, 10 or 12 mg/kg; LGM Pharma,
Nashville, TN) and clozapine-N-oxide (CNO) (2 mg/kg;
Sigma-Aldrich, Gillingham, UK) were dissolved in 0.9%
NaCl and injected intraperitoneally (i.p.) at a volume of
10 ml/kg body weight.
Stereotaxic Viral Vector Injection
Male and female 5-HT2CR
CRE:YFPmice were injected bilat-
erally with 0.25 μl AAV-hSyn-DIO-hM3D(Gq)-mCherry,
AAV-hSyn-DIO-hM4D(Gi)-mCherry or AAV-DIO-
mCherry (University of North Carolina Vector Core
Facilities, Chapel Hill, NC) into the VTA (stereotaxic
coordinates, millimeters from bregma: antero-posterior
− 3.16 ; medio-lateral ± 0.56; dorso-ventral − 4.5) using a
stereotaxic frame (see Supplementary Information for
further details). We did not observe significant sex
differences between treatment responses to food intake
(5-HT2CR
CRE:YPF::hM3Dq-mCherry
VTA: n= 14; F1,10= 2.78;
NS; 5-HT2CR
CRE:YPF::hM4Di-mCherry
VTA: n= 14;
F1,10= 1.12; NS) or the breakpoint in the ad libitum fed (5-
HT2CR
CRE:YPF::hM3Dq-mCherry
VTA: n= 15; F1,11= 1.36; NS;
5-HT2CR
CRE:YPF::hM4Di-mCherry
VTA: n= 29; F1,25= 0.440;
NS) or food-deprived conditions (5-HT2CR
CRE:YPF::hM3Dq-
mCherryVTA: n= 15; F1,11= 0.216; NS; 5-HT2CR
CRE:YPF::
hM4Di-mCherry
VTA: n= 30; F1,26= 0.533; NS) and thereby
combined data with male and female mice.
Operant Conditioning
The mice were individually housed and trained on a PR
schedule based on an exponential progression derived from
the formula (5 × e0.2n)− 5, rounded to the nearest integer,
where n is the position in the ratio sequence (Richardson and
Roberts, 1996; see Supplementary Information for further
details). The breakpoint was defined as the last ratio
completed before 5 min elapsed without any responding or,
when this criterion was not met within the session, the
highest completed ratio (Olarte-Sanchez et al, 2012). The
mathematical model (Bradshaw and Killeen, 2012) used to
analyze PR performance comprises three key equations. The
parameters of these equations provide separate numerical
indices of the motivational impact of the reinforcer and the
motor capability of the organism. The linear waiting
equation (Wynne et al, 1996) is used to predict the post-
reinforcement pause in each ratio (TP,i) from the time taken
to complete the preceding ratio (total time, TTOT,i− 1):
TP;i ¼ T0 þ k TTOT;i1; ð1Þ
where T0 is the initial post-reinforcement pause and k is the
slope of the linear waiting function. Two further equations
define running response rate, RRUN, and overall response
rate, ROVERALL, in successive ratios of the schedule:
RRUN;i ¼ 1
d 1þ TTOT;i1=a
  ð2Þ
ROVERALL;i ¼ NiTTOT;i: ð3Þ
The parameters δ and a are the fundamental ‘motor’ and
‘motivational’ parameters of the model: δ expresses the
minimum time needed to execute a response, and a the
duration of behavioral activation induced by a single
reinforcer (Bradshaw and Killeen, 2012; Killeen, 1994; see
Supplementary Information for further details).
Food Intake
The mice were individually housed and habituated for 5 days
in TSE Phenomaster chambers (TSE, Bad Homburg,
Germany) that record food intake automatically using weight
sensors attached to food containers suspended from the
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ceiling. On each treatment day, 30 min before the onset of
the dark cycle, the food hopper was automatically closed and
the mice were injected with treatment (saline, lorcaserin or
CNO). At the onset of the dark cycle, the food hopper was
opened and chow intake was recorded for the next hour.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on coronally
sectioned 4% paraformaldehyde fixed brain tissue using
methods previously reported (Burke et al, 2016) using the
following primary antibodies to detect immunoreactivity
(IR) for c-fos (#2672548, 1:5000, Millipore) or immunofluor-
escence (IF) for 5-HT2CR (#L1813, 1:300; Santa Cruz
Biotechnology), c-fos (#L1610; 1:800, Santa Cruz Biotechnol-
ogy), γ-aminobutyric acid (GABA) synthesizing enzyme
glutamic acid decarboxylase (GAD; #J2804; 1:150, Santa Cruz
Biotechnology), the dopamine (DA) synthesizing enzyme
tyrosine hydroxylase (TH; #2716631; 1:1000, Millipore),
green fluorescent protein (GFP; #GR279236-1; 1: 800,
Abcam), or mCherry (#31089; 1:800, Rockland). Images
were acquired using an Axioskop II microscope (Carl Zeiss,
Figure 1 Effect of lorcaserin on food intake and operant responding. (a) Lorcaserin 10 mg/kg reduced 1 h chow intake (n= 14). (b) Lorcaserin 3 and 10 mg/
kg reduced the breakpoint when mice were in ad libitum condition (n= 9). (c) Lorcaserin 10 mg/kg reduced the breakpoint when mice were in food-restricted
condition (n= 9). (d–f) Effect of lorcaserin on performance on the progressive-ratio schedule. Ordinate, response rate; abscissa, response/reinforcer ratio, N.
Points are group mean data: unfilled symbols indicate running response rate, filled symbols indicate overall response rate. The curves are best-fit functions
defined by equations (2) and (3). (g) Schematic of the location of the VTA defined by the Mouse Brain Atlas (Paxinos and Franklin, 2001). (h) Lorcaserin 7 and
12 mg/kg increased FOS-IF (blue) within the VTA (n= 6–7 per group). (i–k) FOS-IF (blue) within the VTA following administration of vehicle, lorcaserin 7 or
12 mg/kg (scale bar: 100 μm). All the data are presented as mean± SEM. ∗po0.05; ∗∗po0.01; ∗∗∗po0.001.
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Germany), processed with Adobe Photoshop (Adobe Sys-
tems Software, Ireland) and analyzed with Image J software
(NIH). For IHC quantification analysis, the VTA was defined
using the Mouse Brain Atlas (Paxinos and Franklin, 2001)
and sections containing the VTA (from bregma − 2.92 to
− 3.88 mm) were counted bilaterally (see Supplementary
Information for further details).
Electrophysiology
Egith-to-twelve–week-old 5-HT2CR
CRE:YFP mice were deeply
and terminally anesthetized with sodium pentobarbital and
then decapitated. The brain was rapidly removed and placed
in an ice-cold oxygenated (95%O2/5%CO2) high sucrose
‘slicing’ solution. Coronal slices containing the VTA were
prepared and immediately transferred to a ‘recording’
solution in a continuously oxygenated holding chamber at
35°C for a period of 25 min. Subsequently, the slices were
allowed to recover in the ‘recording’ solution at room
temperature for a minimum of 1 h before recording.
All patch clamp recordings were made using multiclamp
700B amplifier, and the data were filtered at 2 kHz and
digitized at 10 kHz (see Supplementary Information for
further details).
Statistics
For lorcaserin treatment PR and food intake experiments, the
weight of the food consumed, the estimates derived from the
mathematical model and the breakpoint were analyzed using
analysis of variance (ANOVA) with repeated measures for
treatment (lorcaserin dose) with Dunnett’s post hoc test. For
the chemogenetic food intake and PR experiments, the
weight of the food consumed, estimates derived from the
mathematical model and the breakpoint were analyzed using
ANOVA (group [AAV-hM3D(Gq)), AAV-mCherry] × treat-
ment [vehicle, CNO]) or (group [AAV-hM4D(Gi)), AAV-
mCherry] × treatment [vehicle, CNO]) with repeated mea-
sures for treatment, and post hoc comparisons using Tukey’s
test. A significance criterion of po0.05, two-tailed, was
adopted in all the statistical analyses.
RESULTS
5-HT2CR Agonist Lorcaserin Reduces Food Intake and
Decreases Operant Responding for Food Reward
Consistent with previous reports (Fletcher et al, 2009;
Thomsen et al, 2008; Burke et al, 2014), lorcaserin
significantly reduced home cage ad libitum chow intake
compared with saline (n= 14; F2,26= 11.76; po0.001;
Figure 1a). To assess the effect of lorcaserin on food-
motivated behavior, the mice were trained on a PR schedule
and tested during two conditions: ad libitum fed and food
restricted. In the ad libitum fed condition, lorcaserin 3 and
10 mg/kg significantly reduced the breakpoint compared
with vehicle (n= 9; F2,16= 11.76; po0.001; Figure 1b). The
breakpoint was also reduced by 10 mg/kg lorcaserin during
the food restricted condition (n= 9; F2,16= 10.99; po0.01;
Figure 1c). Further analysis of performance on the PR
schedule during the food-restricted condition indicated that
RRUN declined monotonically towards zero, whereas
ROVERALL rose to a peak before declining towards zero. In
accordance with the mathematical model, response rates
conformed closely to equations (2) and (3) (R2= 0.981
[vehicle], 0.990 [lorcaserin 3 mg/kg], and 0.978 [lorcaserin
10 mg/kg]) and post-reinforcement pause duration in
successive ratios was linearly related to the prior inter-
reinforcer interval, as indicated by values of R2 above 0.9
(Figures 1d–f). Lorcaserin 3 and 10 mg/kg significantly
increased the value of k (n= 9; F2,16= 14.46; po0.0001;
Supplementary Figure S1D), while having no significant
effect on the ‘motivational’ parameter, a, (n= 9; F2,16= 0.31;
NS; Supplementary Figure S1A) or T0 (n= 9; F2,16= 0.93; NS;
Supplementary Figure S1C). The ‘motor’ parameter, δ, was
increased by lorcaserin, the effect of 10 mg/kg being
statistically significant (n= 9; F2,16= 19.6; po0.0001;
Supplementary Figure S1B). These data suggest that
lorcaserin significantly reduces operant responding for food
reward by impacting motor processes.
Lorcaserin Increases the Activity of VTA Neurons
The VTA is a structure involved in motivation, food intake
and motor function. To determine whether lorcaserin
influences the activity of VTA neurons, the mice were
treated with vehicle or lorcaserin (7 or 12 mg/kg) and
brains were processed for FOS-IF. First, it was confirmed
that 7 or 12 mg/kg of lorcaserin reduced chow intake
(n= 7–8 per group; F2,19= 8.12; po0.001; Supplementary
Figure S2A) and the breakpoint in both the ad libitum
(n= 25; F2,48= 41.65; po0.0001; Supplementary Figure S2B)
and food-restricted conditions (n= 25; F2,48= 23.58;
po0.0001; Supplementary Figure S2C). Next, we
assessed VTA FOS-IF and observed that lorcaserin
significantly increased FOS-IF compared with vehicle
(n= 6–7 per group; F2,17= 17.27; po0.0001; Figures 1g–k).
These data indicate that doses of lorcaserin that reduced food
intake and operant responding increase the activity of VTA
neurons.
Lorcaserin Increases the Activity of VTA 5-HT2CR
Expressing GABA-Ergic Neurons
To characterize the neurochemical identity of 5-HT2CR
expressing VTA neurons, we intercrossed a 5-HT2CR
CRE line
with a ROSA26EYFP line (Figure 2a) to generate 5-HT2CR
CRE:
YPFmice. In agreement with previous reports of endogenous
5-HT2CR expression (Bubar and Cunningham, 2007; Bubar
et al, 2011), we observed that 5-HT2CR
CRE:YFPpositive cells
were widely expressed within the VTA and co-localized with
5-HT2CR-IF (Figure 2c). To explore the neurochemical
phenotype of VTA 5-HT2CR expressing neurons, we
performed dual-IHC for GPF (5-HT2CR) and GAD67
(GABA) or TH (dopamine). In line with previous reports
using a 5-HT2CR antibody (Bubar and Cunningham, 2007;
Bubar et al, 2011), we found that 5-HT2CR
CRE:YPFis expressed
with both GAD67 and TH neurons (Figures 2d and e).
Specifically, we observed that the majority of VTA
5-HT2CR
CRE:YPFexpressing neurons were GAD67 positive
(69%), whereas a significantly smaller percentage
co-expressed TH (27%) (n= 3 per group; t(4)= 11.69;
po0.001; Figure 2b and Supplementary Figure S3). These
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data suggest that 5-HT2CRs are predominantly positioned to
influence the activity of GABAergic VTA neurons.
We next evaluated the neurochemical phenotype of
5-HT2CR expressing neurons responsive to lorcaserin treat-
ment. 5-HT2CR
CRE:YFP mice were treated with vehicle or
lorcaserin (7 or 12 mg/kg) and tissue processed for triple-
IHC for GFP, FOS and GAD67 or TH. Lorcaserin
significantly and dose-dependently increased the activity
(FOS-IR) of GAD67-positive 5-HT2CR expressing VTA
neurons (n= 3 per group; F2,6= 23.3; po0.001; Figures
3a–c and g), but had no effect on TH-positive 5-HT2CR
expressing VTA neurons (n= 4 per group; F(2,9)= 0.52; NS;
Figures 3d–f and h). These findings suggest that lorcaserin at
doses that reduce food intake and PR responding for food
reward increase the activity of VTA GABAergic, but not
dopaminergic neurons.
Chemogenetic Activation of VTA 5-HT2CR Expressing
Neurons Reduce Food Intake and Operant Responding
We next considered whether selective activation or inhibition
of VTA 5-HT2CR expressing neurons was able to influence ad
libitum food intake or operant responding for food reward. To
investigate this, 5-HT2CR
CRE:YPFmice received bilateral VTA
injections with AAVs that mediate the Cre-dependent
expression of designer receptors exclusively activated by
designer drugs (DREADDs; expressed as DREADD-
mCherry fusion proteins, hM3Dq; 5-HT2CR
CRE:YPF::hM3Dq-
mCherryVTA) (Figure 4a). DREADDs are designer muscarinic
receptor variants that can only be activated by an otherwise
biologically inert designer drug, CNO (Alexander et al, 2009).
We first confirmed that DREADD-fused mCherry reporter
protein was expressed in the VTA (Figure 4a). Next, we
demonstrated that CNO activated 5-HT2CR
CRE:YPF::hM3Dq-
Figure 2 5-HT2CR
CRE:YFP VTA neurons co-express GABA and dopamine. (a) A 5-HT2CR
CRE mouse line in which Cre recombinase is driven by a 5-HT2CR
promoter was intercrossed with a ROSA26-stop-EYFP reporter mouse to generate a 5-HT2CR
CRE:YFP line to facilitate the visualization of VTA 5-HT2CR
expressing cells. (b) VTA 5-HT2CR
CRE:YFP containing neurons (GFP-IF) have a greater co-expression with GAD67-IF compared with TH-IF (n= 4 per group,
po0.001). (c) VTA 5-HT2CRCRE:YFP (GFP-IF; green) are co-localized (overlay, yellow) with endogenous 5-HT2CR-IF (red). (d) VTA 5-HT2CRCRE:YFP (GFP-IF;
green) containing neurons and GAD67 (red) are co-localized (yellow). (e) VTA 5-HT2CR
CRE:YFP (GFP-IF; green) containing neurons and TH (red) are co-
localized (yellow). All the data are presented as mean± SEM. ∗∗∗po0.001. Scale bar: 100 μm.
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mCherryVTA cells with whole-cell electrophysiological record-
ings in ex vivo VTA slices (n= 4/4, 100% responsive;
Figure 4b) and in vivo using FOS-IR (n= 3 per group;
t(4)= 17.45; po0.0001; Figures 4c–e).
Subsequently, we examined the effect of chemogenetic
activation of VTA 5-HT2CR expressing neurons on feeding
behavior. The administration of CNO significantly reduced
ad libitum chow intake compared with vehicle in the home
cage in 5-HT2CR
CRE:YPF::hM3Dq-mCherry
VTA mice (n= 14;
F1,12= 5.47; po0.05; Figure 4f). These data suggest that
activation of VTA 5-HT2CR expressing neurons is sufficient
to significantly reduce food intake. To assess the effect of
activation of VTA 5-HT2CR expressing neurons on food-
motivated behavior, 5-HT2CR
CRE:YPF::hM3Dq-mCherry
VTA
mice were trained on a PR schedule. The administration of
CNO significantly reduced the breakpoint in both the ad
Figure 3 Lorcaserin increases c-Fos in VTA 5-HT2CR GABAergic, but not dopamine neurons. (a-c) c-Fos expression (FOS-IR, gray) in VTA 5-HT2CR
containing neurons (GFP-IF, green) co-expressing GAD67 (GAD67-IF, red) in 5-HT2CR
CRE:YFP mice following (a) vehicle, (b) lorcaserin 7 mg/kg or (c) 12 mg/kg
administration. (d–f) c-Fos expression (FOS-IR, gray) in VTA 5-HT2CR containing neurons (GFP-IF, green) co-expressing TH (TH-IF, red) in 5-HT2CR
CRE:YFP
mice following (d) vehicle, (e) lorcaserin 7 mg/kg or (f) 12 mg/kg administration. (g) Lorcaserin dose-dependently increases FOS-IR in GAD67-positive 5-
HT2CR expressing neurons (n= 4 per group, po0.001), but not in (h) TH-positive 5-HT2CR expressing neurons (n= 4 per group, NS). All the data are
presented as mean± SEM. ∗po0.05; ∗∗po0.01. Scale bar: 50 μm.
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libitum fed (n= 15; F1,13= 5.11; po0.05; Figure 4g) and
food-restricted (n= 15; F1,13= 21.5, po0.001; Figure 4h)
conditions in 5-HT2CR
CRE:YPF::hM3Dq-mCherry
VTA mice
compared with vehicle treatment. Further analysis revealed
that RRUN declined monotonically towards zero, whereas
ROVERALL rose to a peak before declining towards zero. In
accordance with the mathematical model, response rates
conformed closely to equations (2) and (3) (control group
[AAV-mCherry]: R2= 0.960 [vehicle], 0.947 [CNO 2mg/kg];
experimental group [AAV-hM3D (Gq)]: R2= 0.961 [vehicle],
0.979 [CNO 2mg/kg]) (Figures 4i–j). Quantitative analysis
indicated a reduction of a (n= 15; F1,13= 6.6, po0.05), but
no change in δ (n= 15; F1,13= 1.70; NS). These results are
consistent with a reduction in the incentive value of the
reinforcer without a concomitant impairment of motor
competence (Supplementary Figure S2A and B). Activation
of VTA 5-HT2CR expressing neurons significantly increased
the value of k (n= 15; F1,13= 12.6; po0.01; Supplementary
Figure S2D), while having no effect on T0 (n= 15; F1,13= 1.3;
NS; Supplementary Figure S2C). Collectively, these data
indicate that the selective activation of VTA 5-HT2CR
expressing neurons is sufficient to significantly reduce home
Figure 4 Chemogenetic activation of VTA 5-HT2CR neurons reduces food intake and operant responding for food reward. (a) Representative image of
Cre-dependent expression of hM3Dq-mCherry specifically within the VTA of a 5-HT2CR
CRE:YFP mouse. (b) Firing rate of 5-HT2CR
CRE:YPF::hM3Dq-mCherry
VTA
neurons increased upon 10 μM CNO application. (c–e) CNO 2 mg/kg increased FOS-IR within 5-HT2CR
CRE:YPF::hM3Dq-mCherry
VTA compared with vehicle
(n= 3 per group). (f) CNO 2 mg/kg reduced 1 h chow intake (n= 14, po0.05). (g) CNO 2 mg/kg reduced the breakpoint in the experimental group [AAV-
hM3D (Gq)] compared with control [AAV-mCherry] in ad libitum condition (n= 15) and (h) food-restricted condition (n= 15). (i and j) Effect of
chemogenetic activation of VTA 5-HT2CR neurons on performance on a PR schedule. Ordinate, response rate; abscissa, response/reinforcer ratio, N. Points
are group mean data: unfilled symbols indicate running response rate, filled symbols indicate overall response rate. The curves are best-fit functions defined by
equations (2) and (3). All the data are presented as mean± SEM. ∗po0.05; ∗∗po0.01; ∗∗∗po0.001. Scale bar: 100 μm.
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cage food intake and operant responding for food reward,
without altering motor performance.
To investigate whether VTA 5-HT2CR expressing neurons
are required for normal food intake and reward processing,
we chemogenetically silenced VTA 5-HT2CR expressing cells.
Specifically, 5-HT2CR
CRE:YPFmice received bilateral VTA
injections with AAVs that mediate the Cre-dependent
expression of inhibitory (Gi) DREADD-mCherry fusion
protein, hM4Di; 5-HT2CR
CRE:YPF::hM4Di-mCherry
VTA
(Figure 5a). First, we performed patch-clamp recordings in
ex vivo 5-HT2CR
CRE:YPF::hM4Di-mCherry
VTA slices to con-
firm the inhibitory effect of CNO on cell activity. Bath
application of CNO reduced firing rate in 8/8 5-HT2CR
CRE:
YPF::hM4Di-mCherry
VTA expressing neurons (Figure 5b).
The effect of CNO administration on homeostatic food
intake and food-motivated behavior in 5-HT2CR
CRE:YPF::
hM4Di-mCherry
VTA mice was then assessed. Treatment with
CNO had no effect on home cage chow intake (n= 14;
F1,12= 0.33; NS; Figure 5c) or PR responding for food
reward in ad libitum (n= 29; F1,27= 1.93; NS; Figure 5d) or
food-restricted conditions (n= 30; F1,28= 0.05; NS; Figure 5e)
compared with vehicle.
Though this chemogenetic approach suggests that redu-
cing the activity of VTA 5-HT2CR expressing neurons via 5-
HT2CR
CRE:YPF::hM4Di-mCherry
VTA is not sufficient to alter
normal food intake or motivation for food reward, targeted
genetic knockdown of VTA 5-HT2CRs is required to
establish the specific function of VTA 5-HT2CRs in food
intake and motivation for food reward. However, of
translational relevance to human obesity treatment, we
observed that activation of this discrete subset of VTA
neurons is sufficient to produce a significant effect on
multiple types of feeding behavior. These include, ad libitum
food intake in the home cage and the PR task where the
incentive value of food reward is manipulated by food-
deprivation levels. Activation of this small subset of 5-HT2CR
expressing neurons produced a consistent reduction in the
feeding behavior that was not associated with changes in
motor performance, suggesting that the effect is directly
related to incentive motivation.
DISCUSSION
Due to its prevalence and deleterious health consequences,
obesity is one of the primary global healthcare challenge of
Figure 5 Chemogenetic inhibition of VTA 5-HT2CR neurons does not alter food intake or operant responding for food reward. (a) Representative image of
Cre-dependent expression of hM4D(Gi)-mCherry specifically within the VTA of a 5-HT2CR
CRE:YFP mouse. (b) Firing rate of 5-HT2CR
CRE:YPF::hM4Di-
mCherryVTA neurons decreased upon 10 μM CNO application. (c) CNO 2 mg/kg had no effect on 1 h chow intake (n= 14). (d) CNO 2 mg/kg had no
effect on the breakpoint in the experimental group [AAV-hM4D (Gi)] compared with the control [AAV-mCherry] in ad libitum condition (n= 29) or
(e) food-restricted condition (n= 30).
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the 21st century. Discerning a new means to combat the
obesity epidemic is therefore of paramount clinical impor-
tance. Obesity is primarily due to the consumption of food in
excess of the body’s energetic requirements, energy that is
then stored as fat. 5-HT, via action at 5-HT2CRs, produces a
potent inhibitory effect on the feeding behavior. Capitalizing
on this effect, the 5-HT2CR agonist lorcaserin, an obesity
medication recently approved by the US FDA, reduces body
weight by decreasing ad libitum food intake (Martin et al,
2011) and promoting satiety (Higgs et al, 2016).
However, as 5-HT2CRs are expressed throughout the brain,
precisely where and how lorcaserin exerts its effects upon
feeding behavior has not been fully defined. Here we
investigated a specific subset of 5-HT2CR expressing neurons
that are sufficient to reduce food intake and moreover, food-
motivated behavior. In particular, we were interested in food
motivation because the drive or ‘motivation’ to consume
food in the absence of hunger is a primary behavior
underpinning the development of obesity. Targeting and
reducing this specific aspect of feeding behavior would be
particularly attractive for the treatment of obesity.
Obesity Medication Lorcaserin Reduces Food Intake and
Operant Responding for Food Reward
Previous research has focussed on the role of 5-HT2CRs in
the modulation of homeostatic feeding by influencing the
activity of the hypothalamic melanocortin system (Burke
et al, 2016; Doslikova et al, 2013; Heisler et al, 2002; Lam
et al, 2008; Xu et al, 2008). Here we observed that lorcaserin
produced the expected reduction in home cage ad libitum
intake of standard laboratory chow. Given that 5-HT2CRs are
also expressed in the VTA (Bubar and Cunningham, 2007;
Bubar et al, 2011), a brain region associated with food and
drug reward (DiLeone et al, 2012), we investigated
lorcaserin’s effects on a PR schedule using a mathematical
model (Bradshaw and Killeen, 2012) derived from Killeen’s
Mathematical Principles of Reinforcement (MPR, Killeen,
1994). In agreement with previous reports in rats (Bezzina
et al, 2015; Bradshaw and Killeen, 2012; Olarte-Sanchez et al,
2013, 2015; Valencia-Torres et al, 2014), our results indicate
that operant behavior maintained by PR schedules is well
described by the mathematical model in mice (Bradshaw and
Killeen, 2012). Progressive ratio schedules are widely used to
assess the effects of neuropharmacological interventions on
motivation. This practice is based on the assumption that the
traditional index of performance, the breakpoint, provides a
quantitative index of motivation, or the incentive value of the
reinforcer (Hodos, 1961; see Killeen et al, 2009). However,
there is considerable evidence that the breakpoint is sensitive
to motor as well as motivational factors (Aberman et al,
1998; Skjoldager et al, 1993). The mathematical model
incorporates separate parameters that represent motivational
and motor processes (a and δ, respectively); a change in the
value of either parameter may give rise to a change in the
breakpoint (Bradshaw and Killeen, 2012). Our findings
indicated that systemically administered lorcaserin increased
the value of δ without affecting a. The present finding is
consistent with the results of Bezzina et al (2015) that
showed that a reduction of the breakpoint induced by 5-HTR
agonists mCPP and Ro-600175 was associated not with a
reduction of the value of a, but with an increase of the value
of δ, which could be reversed by 5-HT2CR antagonist
SB-242084. These findings suggest that systemic treatment
with 5-HT2CR agonists suppress operant performance via a
detrimental effect on motor processes, thereby confounding
interpretations of effects on motivational processes.
Lorcaserin Increases the Activity of VTA 5-HT2CR
GABAergic Neurons
Given that 5-HT2CRs are expressed in multiple brain regions
where they are positioned to perform different functions
(including motor functions), we were interested in discern-
ing a specific subset of 5-HT2CRs capable of modulating food
motivation without interfering with motor function. We
observed that doses of lorcaserin that reduce food intake and
PR responding increase the activity of VTA neurons. As the
VTA neuronal population is phenotypically heterogeneous,
we characterized the neurochemical phenotype of 5-HT2CR
expressing neurons and their response to lorcaserin using of
a new mouse line (5-HT2CR
CRE:YFP; Burke et al, 2016). We
observed that VTA 5-HT2CR expressing neurons were
mainly co-expressed with GABA and a much smaller
percentage were co-expressed with dopamine. Consistent
with this anatomical localization, lorcaserin significantly and
dose-dependently increased the activity of GABA-ergic
neurons. This is consistent with the notion that activation
of 5-HT2C receptor expressing neurons of the VTA
predominantly stimulates GABA-ergic neurons thereby
suppressing the dopaminergic output of this structure
(Filip et al, 2012; Navailles et al, 2008).
Selective Chemogenetic Activation of VTA 5-HT2CR
Expressing Neurons Reduces Food Intake and Operant
Responding for Food Reward
Next, using a chemogenetic approach (Urban and Roth,
2015), we investigated the specific function of 5-HT2CR
expressing cells within the VTA. Here we observed that
selective activation of VTA 5-HT2C receptor expressing
neurons was sufficient to significantly reduce ad libitum
chow intake (59%) to a degree comparable with systemic
lorcaserin treatment (60%).
Next, we explored the role of VTA 5-HT2C receptor
expressing neurons in food-motivated behavior. We ob-
served that chemogenetic activation of VTA 5-HT2C receptor
expressing neurons caused suppression of responding in the
PR schedule and a reduction in the breakpoint both when
mice were food restricted and fed ad libitum. Further
quantitative analysis revealed a reduction of a but no change
in δ, consistent with a reduction of the incentive value of the
reinforcer with no concomitant impairment of motor
competence. This is in line with previous research that
demonstrated that 5-HT2CRs within the VTA exert an
inhibitory influence upon the mesoaccumbens dopamine
(DA) system (Navailles et al, 2008) attenuating the effort-
based intake of food (Salamone and Correa, 2013). Systemic
administration of lorcaserin may engage additional systems
that mask the specific motivational effect seen with acute
stimulation of VTA 5-HT2C receptor expressing neurons. For
example, 5-HT2CRs are expressed in several structures within
the basal ganglia, where they exert influence over
VTA 5-HT2CRs regulate food motivation
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extrapyramidal motor functions (Graves et al, 2013;
Miguelez et al, 2014).
Although activation of VTA 5-HT2CR expressing neurons
produced a potent reduction in the feeding behavior,
inhibition of these neurons did not alter food intake or PR
responding for food reward. Targeted genetic knockdown
studies of VTA 5-HT2CRs are required to establish the
necessity of this subpopulation on the regulation of food
intake and motivation for food reward.
SUMMARY
Here we identify a new subpopulation of 5-HT2CRs that are
capable of reducing homecage food intake and food-
motivated behavior without interfering with motor function,
findings that reveal a new site of 5-HT2CR activation to
pharmacologically exploit in the development of novel
obesity medication. Given that one of the primary factors
in the development of human obesity is enhanced motivation
to consume food, these findings are particularly germane to
the development of new selective medications to abate the
obesity epidemic.
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